Thelansis

DiGeorge Syndrome (DGS) Market Outlook Thelansis’s “DiGeorge Syndrome (DGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential DiGeorge Syndrome (DGS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajec...

DiGeorge Syndrome (DGS) Market Outlook Thelansis’s “DiGeorge Syndrome (DGS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential DiGeorge Syndrome (DGS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). DiGeorge Syndrome (DGS) Overview DiGeorge syndrome (DGS) is a congenital disorder with a broad phenotypic presentation caused primarily by a microdeletion of chromosome 22 at 22q11.2. This mutation fails in the proper development of the pharyngeal pouches, which are responsible for the embryologic development of the middle and external ear, maxilla, palatine tonsils, mandible, thyroid, parathyroids, thymus, aortic arch, and cardiac ou...

  DiGeorge syndrome (DGS) is a congenital disorder with a broad phenotypic presentation caused primarily by a microdeletion of chromosome 22 at 22q11.2. This mutation fails in the proper development of the pharyngeal pouches, which are responsible for the embryologic development of the middle and external ear, maxilla, palatine tonsils, mandible, thyroid, parathyroids, thymus, aortic arch, and cardiac outflow tract. DGS symptoms include cardiac anomalies, recurrent infections, abnormal facies, thymic hypoplasia or aplasia, cleft palate, developmental delay, and hypocalcemia. DGS symptoms include a thymus that is absent or hypoplastic, cardiac abnormalities, hypocalcemia, and parathyroid hypoplasia. The absence of thymic tissue, the organ responsible for T lymphocyte development, is the most concerning feature of DGS. A complete lack of the thymus, which is extremely rare and affects less than 1% of DGS patients, is associated with severe combined immunodeficiency (SCID). T-cells ...